Parfenov A I, Poleva N I
Klin Med (Mosk). 2000;78(12):49-50.
The efficiency of laxigal (sodium picosulfate) was evaluated in 66 patients aged 38-73 years with the irritated bowel syndrome (IBS), inert colon, and dolichocolon. Twenty-eight patients had defecations twice a week, 26 once a week or less. Twelve patients had no spontaneous defecations. Laxigal was administered in a dose of 10-24 droplets before sleeping. Good effect was attained in 42 (64%) patients and satisfactory in 24 (36%). Good effect is more often observed in patients with IBS and dolichocolon, while in patients with inert colon the results were usually no better than satisfactory. After long (3 weeks and longer) therapy with laxigal its dose could be reduced by 30-50% without loss of effect. Laxigal induces no diarrhea, abdominal pain, decrease in electrolyte composition or other serum shifts, does not disorder hepatorenal functions.
对66例年龄在38至73岁之间、患有肠易激综合征（IBS）、惰性结肠和冗长结肠的患者评估了拉西加（比沙可啶钠）的疗效。28例患者每周排便两次，26例每周排便一次或更少。12例患者无自主排便。睡前服用拉西加，剂量为10至24滴。42例（64%）患者效果良好，24例（36%）患者效果满意。在患有肠易激综合征和冗长结肠的患者中更常观察到良好效果，而在患有惰性结肠的患者中，结果通常不超过满意。在使用拉西加进行长期（3周及更长时间）治疗后，其剂量可减少30%至50%而不影响疗效。拉西加不会引起腹泻、腹痛、电解质成分降低或其他血清变化，也不会扰乱肝肾功。
